It is demonstrated that pairing a genomic language model with widely available clinical imaging can serve as a hypothesis-free discovery tool for gene--imaging associations invisible to conventional approaches.
Abstract
The function of many genes is still unknown, and conventional driver-discovery methods, which rely on how frequently a gene is mutated, cannot assess genes that are only rarely affected. Here we pair Evo~2-based genome analysis with routine clinical imaging to identify gene--phenotype associations at genome-wide scale. For every somatic mutation across three TCGA cohorts (cRCC=clear cell renal cell carcinoma, HCC=hepatocellular carcinoma, and BC=breast cancer; $n = 340$ total), Evo~2 predicts a severity score, with no task-specific training. Per-gene severity summaries are then correlated with radiomic features extracted from paired tumor segmentations, controlling for total mutation burden. In TCGA-cRCC ($n = 162$), this sweep recovers established renal-cancer drivers and identifies 46 additional genes reaching false discovery rate (FDR) significance absent from curated cancer-gene panels, several of which are Mendelian ciliopathy and cytoskeletal-disease genes. These results demonstrate that pairing a genomic language model with widely available clinical imaging can serve as a hypothesis-free discovery tool for gene--imaging associations invisible to conventional approaches.
Convergent genetic, transcriptomic, and protein-level evidence prioritizes CDC16 as a GC-associated candidate tissue marker whose expression is closely linked to proliferative activity.
Fan Xue, Dao-Cheng Wu, Xu Zhang· International Journal of Bio...· 0 citations
TP53 and FOXA1 mutations, observed in primary and metastatic castration-resistant prostate cancer, were associated with aggressive disease phenotypes and potential therapeutic resistance, and these findings highlight TP53 and FOXA1 as promising biomarkers and potential therapeutic targets in prostate cancer.
Background/Objectives: Breast cancer (BC) is the most frequently diagnosed malignancy and a leading cause of cancer-related mortality in women worldwide. This disease is highly heterogeneous and dynamic, and chromosomal instability (CIN) plays a key role in the acquisition of these traits by generating genetic diversit...
María Paula Meléndez-Flórez, N. Rangel, Milena Rondón-Lagos et al.· Biomedicines· 0 citations
An open-source Bayesian inference tool that determines the multiplicity and copy number of driver mutations from tumor sequencing datasets is presented, an open-source Bayesian inference tool that determines the multiplicity and copy number of driver mutations from tumor sequencing datasets.
N. Calonaci, E. Krasniqi, D. Čolić et al.· Nature Genetics· 0 citations
Triple-negative breast cancer (TNBC) is characterized by aggressive behaviour, high tumor heterogeneity, and an increased likelihood of recurrence and early metastasis. These factors hinder successful treatment. Genetic diagnosis enables personalized clinical recommendations and treatment options. The objective of this...
D. Alzate, A. Y. Sánchez, Yovana Pacheco et al.· PLoS ONE· 0 citations
Evidence indicates that molecularly guided therapy, particularly when integrated with clinicopathological data, can improve survival and expand treatment options beyond empirical chemotherapy.
K. Tałasiewicz, Michał Mikula, Aleksandra Kapała· Critical reviews in oncology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.